Skip to main content

Table 1 Patients’ characteristics

From: A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma

Patient ID Age/Sex Stage Meta site MSKCC Histology Grade Prior treatment
1802 72/F pT3aN2M1 Lung, LN Poor Clear cell 2 > 3 Sunitinib
1803 72/M pT3bN0M1 Liver, lung, bone Poor Clear cell 3 > 2 IFN-α, radiation
1806 72/F pT4N1M1 Lung, LN Intermediate Clear cell 3 no
1808 75/M pT3aN2M1 Lung, LN, bone Intermediate Unclassified 3 no
1812 61/M pT1bN1M1 LN Intermediate Clear cell 2 > 1> > 3 no
1814 55/M pT3aN0M1 Lung Intermediate Clear cell 2 no
1817 64/F pT3bN1M1 Lung, LN, bone Intermediate Clear cell 3 > 2 no
1823 57/M pT1N0M1 Lung, pleura Intermediate Clear cell 2 > 3 no
  1. MSKCC, Memorial Sloan Kettering Cancer Center risk criteria; LN, lymph node.